Severe Losses Hit EL&F in Q2: A Look at the Market Impact Recently, news from Korea Economic News highlighted the troubling financial performance of EL&F, a leading player in the industry. In the second quarter, the company reported an operational loss of 842 billion won, sparking significant concerns among investors and analysts alike. This downturn…

Investing in Samsung Biologics: Key Insights from Q2 2024 Investing in Samsung Biologics: Key Insights from Q2 2024 The financial market is always buzzing with news and developments, and the recent analysis by Hana Financial Investment’s analyst Park Jae-kyung on Samsung Biologics has caught the attention of investors. In this post, we will delve deeper…

Generous Scholarship Support by Geururami Group Generous Scholarship Support by Geururami Group In a remarkable initiative to encourage academic excellence among engineering students across South Korea, the Geururami Group has generously donated a scholarship fund amounting to 54.6 million KRW. This commendable effort aims to uplift the educational pursuits of young minds and empower them…

Clinical Trial Approval for HLB3-002 by 휴온스랩 Clinical Trial Approval for HLB3-002 by 휴온스랩 Recent news highlights a significant development in the field of biotechnology. 휴온스랩, a leading biotech company, has announced that their recombinant human hyaluronidase, HLB3-002, has received approval for its clinical trial phase 1 (IND) from the Korean Ministry of Food and…

Kospi Market Update: Strong Start Driven by Individual Investors Kospi Market Update: Strong Start Driven by Individual Investors As the trading day unfolded, the Kospi index showcased a robust performance, bolstered significantly by the enthusiastic buying pressure exerted by individual investors. The remarkable trend indicated a growing confidence among local retail investors, leading to a…